See What HealthDay Can Do For You
Contact Us

Dapagliflozin Aids Glycemic Control in Type 2 Diabetes

For patients with poorly controlled diabetes, daily dose stabilizes insulin dosing, reduces weight

TUESDAY, March 20 (HealthDay News) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research published in the March 20 issue of the Annals of Internal Medicine.

To evaluate the efficacy and safety of dapagliflozin, John P.H. Wilding, D.M., of University Hospital Aintree in Liverpool, U.K., and associates randomly assigned 800 patients with inadequately controlled type 2 diabetes, receiving at least 30 units of insulin daily, with or without up to two oral antidiabetic drugs, to receive a daily dose of dapagliflozin (2.5, 5, or 10 mg) or placebo for 48 weeks.

After 24 weeks, the researchers found that patients taking dapagliflozin had a 0.79 to 0.96 percent decrease in mean hemoglobin A1c, compared with a 0.39 percent decrease with placebo. The daily insulin dose decreased by 0.63 units with dapagliflozin compared with an increase of 5.65 units in the placebo group. Dapagliflozin was associated with a decrease of 0.92 to 1.61 kg in body weight, compared with an increase of 0.43 kg in the placebo group. At 48 weeks, these effects were maintained. Patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes compared with the placebo group (56.6 versus 51.8 percent).

"Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major hypoglycemic episodes in patients with inadequately controlled type 2 diabetes mellitus," the authors write.

The study was funded by AstraZeneca and Bristol-Myers Squibb, co-developers of dapagliflozin. Several of the authors are employees of AstraZeneca.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.